FDA Strengthens Inspections Of Chinese Drug Firms In Heparin Aftermath
This article was originally published in The Tan Sheet
Executive Summary
BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S
You may also be interested in...
Global Rx-360 Consortium Aims To Curb Supply Chain Threats
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
China Taking Regulatory Route To Tighten Oversight Of Health Care Sector
China aims to upgrade supervision of its entire health care sector with an array of regulatory changes for pharmaceuticals and medical devices likely this year, including good manufacturing practice guidelines, according to a leading lawyer in the area of China's life sciences-related issues and legislation
FDA Foreign Offices Are Only The Start To Improving Import Safety – Experts
FDA needs the cooperation of foreign governments to improve import safety, but still could be overwhelmed by rapidly expanding industry overseas and a lack of resources, according to food and drug industry stakeholders